Around 30% of drug candidates fail to progress beyond Phase I healthy volunteer studies, and these failures can be attributed mainly to inappropriate human biopharmaceutical properties
One of Nottingham's leading scientific experts is to address an international audience in Miami at the 32nd annual meeting of the Controlled Release Society from 18-22 June 2005.
Professor Ian Wilding, a founder and scientific adviser to early phase drug development success story Pharmaceutical Profiles, is very much in demand at this keynote conference.
On the second day of the event, he will be presenting at a workshop entitled 'Using scintigraphy to visualise the in vivo targeting properties of colonic delivery systems' and giving a podium presentation focusing on university spin-out companies: 'Forget the lifestyle option and go for gold'.
Wilding recently sold Pharmaceutical Profiles, a spin-out company from the University of Nottingham, for £10 million, so has personal experience of translating academic excellence into commercial success.
He is also chairing a conference session and, on the last day of the conference, is giving a keynote address on 'Overcoming developability problems in oral drug delivery using human absorption and scintigraphic studies'.
Wilding said: "The Controlled Release Society annual meeting is one of the first events we put in our corporate calendar - it is a must-attend event.
"We are also taking part in the exhibition at CRS 2005 alongside my presentations in order to maximise the benefit of the event.
"It is an excellent opportunity to network with industry figures, learn about new drug delivery techniques, and promote the unparalleled expertise Pharmaceutical Profiles has in early drug development".
Pharmaceutical Profiles is an early phase contract research organisation which provides novel solutions in early clinical development.
Since its inception in 1990, Pharmaceutical Profiles's mission has been to improve the decision-making process by offering innovative services to the global pharmaceutical industry.
Around 30% of drug candidates fail to progress beyond Phase I healthy volunteer studies, and these failures can be attributed mainly to inappropriate human biopharmaceutical properties.
Human microdosing studies allow the administration of microgram quantities of drug candidates in man.
This enables safer and more ethical screening studies in man prior to entering Phase I trials and the earlier selection of the optimal compound to advance in development.
Human microdosing studies lead naturally into human drug absorption studies.
Pharmaceutical Profiles utilises the proprietary and patented Enterion capsule to effectively establish the optimal development strategy for today's compounds with their complex oral biopharmaceutical properties.
The company claims to be the world's leading CRO resource for sophisticated medical imaging techniques, such as 2D gamma scintigraphy and 3D Spect (single photon emission computed tomography).
These imaging modalities are incorporated into the oral scintigraphy and GS3 inhaled and nasal studies undertaken for the global pharmaceutical industry.
The company has its headquarters located in Ruddington near Nottingham, UK, and representative offices in the USA and Japan.
